Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A preclinical expansion
January 2020
SHARING OPTIONS:

HAMILTON, N.J.—Late last year, Genesis Drug Discovery & Development (GD3), a member of Genesis Biotechnology Group (GBG), announced the acquisition of the contract research organization New England Discovery Partners (NEDP). The transaction is expected to expand GD3’s preclinical drug research and discovery offerings by enabling the company to provide integrated, single point-of-contact services through the lifetime of a project; streamline all discovery phases; and accelerate projects from discovery through preclinical development.
 
“We’re committed to building an industry-leading, fully integrated drug discovery CRO,” noted Dr. Eli Mordechai, CEO of GBG. “Adding NEDP is another way to differentiate our capabilities in the early drug discovery space. We’re significantly enhancing our portfolio around organic and medical chemistry to better serve our industry partners.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.